Related Experiment Videos
Vasopressin antagonists in heart failure
Ladan Golestaneh1, Ashok Talreja, Thierry H Le Jemtel
1Division of Nephrology, Department of Medicine, Montefiore Medical Center, 111 East 210th Street, Bronx, NY 10467, USA. lgolesta@montefiore.org
Current Heart Failure Reports
|July 23, 2005
Summary
V2 vasopressin receptor antagonists, known as vaptans, offer a new approach to treating heart failure by promoting water excretion and correcting low sodium levels. These drugs address limitations of traditional diuretics, with a major mortality study currently underway.
Area of Science:
- Cardiology
- Nephrology
- Pharmacology
Background:
- Loop diuretics face efficacy limitations and resistance in heart failure patients.
- Mechanisms of loop diuretic resistance include the 'braking phenomenon' and cellular changes in the kidneys.
- The arginine vasopressin system is a key target for novel heart failure therapies.
Purpose of the Study:
- To evaluate the role of V2 vasopressin receptor antagonists in managing heart failure.
- To explore the aquaretic and hyponatremia-correcting effects of vaptans.
- To address the need for alternative treatments beyond loop diuretics.
Main Methods:
- Administration of selective (tolvaptan) and nonselective (conivaptan) V2 vasopressin receptor antagonists.
- Assessment of free-water excretion (aquaresis) as a primary outcome.
- Monitoring of serum sodium levels to evaluate hyponatremia correction.
Main Results:
- Vaptans effectively promote free-water excretion, termed aquaresis.
- These agents demonstrate efficacy in correcting hyponatremia in severe heart failure.
- Vaptans represent a promising therapeutic strategy for heart failure management.
Conclusions:
- V2 vasopressin receptor blockade is a viable strategy for heart failure.
- Vaptans offer a novel mechanism to overcome diuretic resistance.
- Further research, including mortality studies, is crucial for widespread adoption.